When more is not better: 10 &apos;don&apos;ts&apos; in endometriosis management : an ETIC* position statement by L. Alio et al.
†Endometriosis Treatment Italian Club (the list of participating centers and collaborating authors is available at the end of the manuscript in the Appendix)
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Human Reproduction Open, pp. 1–15, 2019
doi:10.1093/hropen/hoz009
OPINION
When more is not better: 10 ‘don’ts’ in
endometriosis management. An ETIC∗
position statement
ETIC Endometriosis Treatment Italian Club†
*Correspondence address. Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic University of Siena,
Viale Bracci, 53100 Siena, Italy. Tel. +39 335.357096; E-mail: errico.zupi@gmail.com https://orcid.org/0000-0003-0735-6301
Submitted on August 13, 2018; resubmitted on December 9, 2018; editorial decision on March 1, 2019
ABSTRACT: A network of endometriosis experts from 16 Italian academic departments and teaching hospitals distributed all over the
country made a critical appraisal of the available evidence and definition of 10 suggestions regarding measures to be de-implemented. Strong
suggestions were made only when high-quality evidence was available. The aim was to select 10 low-value medical interventions, characterized
by an unfavorable balance between potential benefits, potential harms, and costs, which should be discouraged in women with endometriosis.
The following suggestions were agreed by all experts: do not suggest laparoscopy to detect and treat superficial peritoneal endometriosis in
infertile women without pelvic pain symptoms; do not recommend controlled ovarian stimulation and IUI in infertile women with endometriosis
at any stage; do not remove small ovarian endometriomas (diameter<4 cm) with the sole objective of improving the likelihood of conception
in infertile patients scheduled for IVF; do not remove uncomplicated deep endometriotic lesions in asymptomatic women, and also in
symptomatic women not seeking conception when medical treatment is effective and well tolerated; do not systematically request second-
level diagnostic investigations in women with known or suspected non-subocclusive colorectal endometriosis or with symptoms responding
to medical treatment; do not recommend repeated follow-up serum CA-125 (or other currently available biomarkers) measurements in
women successfully using medical treatments for uncomplicated endometriosis in the absence of suspicious ovarian cysts; do not leave women
undergoing surgery for ovarian endometriomas and not seeking immediate conception without post-operative long-term treatment with
estrogen–progestins or progestins; do not perform laparoscopy in adolescent women (<20 years) with moderate–severe dysmenorrhea
and clinically suspected early endometriosis without prior attempting to relieve symptoms with estrogen–progestins or progestins; do not
prescribe drugs that cannot be used for prolonged periods of time because of safety or cost issues as first-line medical treatment, unless
estrogen–progestins or progestins have been proven ineffective, not tolerated, or contraindicated; do not use robotic-assisted laparoscopic
surgery for endometriosis outside research settings.
Our proposal is to better address medical and surgical approaches to endometriosis de-implementing low-value interventions, with the aim to
prevent unnecessary morbidity, limit psychological distress, and reduce the burden of treatment avoiding medical overuse and allowing a more
equitable distribution of healthcare resources.
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Introduction
Management of endometriosis is often dictated by personal convictions
of physicians (and patients) and by local diagnostic–therapeutic paths
and expertise (or lack of ), rather than by robust evidence derived from
adequately designed and conducted pragmatic, randomized, controlled
trials (RCT) (Vercellini et al., 2015). When developing the ESHRE
guideline, the members of the committee noted that ‘One of the
most striking experiences in writing this guideline was the notion that
so many key questions could either not be answered or that only
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little or low-quality data were available. Indeed, many issues could
not be resolved based on the available literature.’ (Dunselman et al.,
2014).
As a consequence, diagnostic and treatment modalities for similar
clinical conditions vary widely, exposing women with endometriosis
to the risk of several potential harms, including those deriving from
medical overuse. In fact, the general tendency to ‘do more’ in medicine
has not spared the endometriosis field (Vercellini et al., 2018a, 2018c).
When managing women with endometriosis, any suggested medical
intervention must be based on clear demonstration that the patient
2 Zupi
might benefit from it, and that the potential harms and the costs are
proportional to the magnitude of the potential benefit.
For these reasons, the Endometriosis Treatment Italian Club (ETIC)
has developed a process to jointly identify those diagnostic and thera-
peutic measures considered to be supported by low-quality evidence
and whose application in women with endometriosis could lead to
the following: an unjustified increase in the number of medical and
surgical procedures; untoward effects and morbidity; a psychological
impact including diagnostic labeling; and a burden of treatment includ-
ing financial impact on individuals and families (Vercellini et al., 2018a,
2018b).
The objectives of the resulting position paper were 2-fold. The
first objective was the selection of a list of 10 low-value medical
interventions that, owing to an unfavorable balance between potential
benefits, potential harms, and costs, in general should be discouraged.
The second objective was to define the uncertainties and potential
downstream consequences of the 10 considered measures to be
discussed when counseling women, with the objective of allowing
them to make the decisions that most suit their priorities and
preferences.
Methods
The ETIC network comprises numerous national endometriosis
experts from 16 university departments and teaching hospitals
distributed all over the country. The list of participating centers and
experts is available at the end of this manuscript. All these regional
referral centers provide expertise and treatment options in the
medical, surgical, and ART areas. One of the aims of the ETIC network
is to define and disseminate high-quality diagnostic and therapeutic
standards to be adopted in various disease forms (Alabiso et al., 2015
and 2016). In the present case, a steering committee circulated a first
round of emails with the objective of defining the final list of medical
interventions to be discouraged in women with endometriosis.
A provisional list was drafted and then jointly discussed during a
2-day binging meeting convened in Verona on 28 and 29 October
2016. On that occasion the list was refined, collectively selecting the
final 10 priority points to be addressed. Participants were then asked
to spontaneously self-propose themselves to be included in 10 sub-
groups, each focused on one specific issue, with the objective of
undertaking a comprehensive literature search on the assigned topic
and of critically assessing the relevant available evidence. In addition to
a comprehensive appraisal of the best available evidence, the guidelines
of major scientific societies (College of Obstetricians and Gynecol-
ogists (ACOG), 2010; Leyland et al., 2010; Practice Committee of
the American Society for Reproductive Medicine, 2012, 2014; Dunsel-
man et al., 2014) and recommendations of internationally recognized
professional associations (Johnson et al., 2013; National Institute for
Health and Care Excellence (NICE), 2017) were consulted to retrieve
further information on the selected topics.
Following the conclusion of the literature evaluation phase, the 10
sub-groups of experts were asked to draft a preliminary short report
including also a summary description of the quality of the evidence and
of the strength of the suggestions. The Grading of Recommendations
Assessment, Development and Evaluation (GRADE) guidelines were
used to define the quality of the evidence regarding each addressed
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issue. This system defines four quality categories (high, moderate,
low, very low) that are applied to a body of evidence regarding both
diagnostic tests and interventions (Schunemann et al., 2008; Balshem
et al., 2011). The direction and strength of clinical suggestions have
been also classified according to the GRADE guidelines (Andrews
et al., 2013a, 2013b), separating them into strong and weak. In the
present case, obviously only the ‘weak-against’ and ‘strong-against’
definitions were taken into consideration, based on the estimates
of effect for undesirable outcomes of interest, confidence in the
estimates of effect, estimates of value, and resource use (Andrews
et al., 2013a, 2013b). ‘Strong’ statements were based on high-quality
evidence against a specific intervention, whereas ‘weak’ statements
were based on moderate- or low-quality evidence. Unlike the GRADE
guidelines, we used the term ‘suggestion’, instead of ‘recommenda-
tion’, as issuing recommendations implies a pre-planned and registered
critical quantitative, and not only qualitative (as here), systematic
analysis of the evidence.
The 10 short reports were circulated by emails to all the members of
the ETIC network, and then collectively examined during a second 2-
day binging meeting that took place in Frascati (Rome) on 31March and
1 April 2017. The controversial aspects were extensively addressed
and a consensus was reached. All the ETIC members eventually agreed
without caveat on the modifications to be implemented.
The 10 sub-groups of experts refined their short reports according
to the shared conclusions that were agreed during the second joint
meeting. The steering committee then further revised the text exclu-
sively with the aim of ensuring a uniform style to the final assembled
report. This was sent to all the ETIC members with a third round of
emails and then definitively discussed, corrected, and approved during
a third joint meeting convened in Catanzaro on 24–25 November
2017. This consensus process was developed with the financial support
of a pharmaceutical company (IBSA Institut Biochimique SA, Lugano,
Switzerland), which is not currently marketing drugs for the treatment
of endometriosis.
Ethical approval
Institutional review board approval was not required for this
manuscript, as only published and de-identified data were used to
define the list of the considered 10 medical interventions to be
discouraged in women with endometriosis.
The 10 ‘Don’ts’ in Endometriosis
Management
Do not suggest laparoscopy to detect and
treat superficial peritoneal endometriosis in
infertile women without pelvic pain
symptoms (quality of the evidence, high;
strong suggestion)
A first pivotal RCT conducted on infertile patients with stages I and II
endometriosis demonstrated a significant improvement in the ongoing
pregnancy rate and live birth rate in women who underwent diagnostic
laparoscopy and ablation of lesions compared to those who received
diagnostic only laparoscopy (Marcoux et al., 1997). However, two
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subsequent smaller RCTs failed to confirm these findings (Parazzini,
1999; Gad and Badroui, 2012). Noteworthy, the most recent study
(Gad and Badroui, 2012) was presented at the International Federation
of Gynecology and Obstetrics in Rome in 2012, but to date has not
been published.
The first Cochrane meta-analysis on the issue included the Canadian
and the Italian studies (Jacobson et al., 2010), whereas the latest one
(Duffy et al., 2014) included the last study but excluded the Italian
one (Parazzini, 1999) because women were allowed to use GnRH
agonists for a few months after surgery. The combined odds ratio
(OR) of ongoing pregnancy or live birth was 1.64 (95% Cl, 1.05–
2.57) and 1.94 (95% CI, 1.20–3.16) for the first and second meta-
analyses, respectively. The number of infertile women that should
undergo destruction of superficial peritoneal endometriosis to achieve
an additional ongoing pregnancy compared with no treatment was
12 and 8, respectively. Therefore, since the prevalence of minimal
or mild endometriosis among women with unexplained infertility is
≤50%, the number needed to benefit rises to more than 24 or 16,
respectively. This compares unfavorably with the efficacy of IVF, whose
rate of success is ∼25% (corresponding to a number needed to be
treated of four) (European IVF-Monitoring Consortium (EIM) for the
European Society of Human Reproduction and Embryology (ESHRE)
et al., 2016).
Accordingly, guidelines issued by major international professional
associations do not support routine laparoscopy for women with
unexplained infertility (Practice Committee of the American Society
for Reproductive Medicine, 2012; Dunselman et al., 2014). This posi-
tion is also endorsed in the National Institute for Health and Care
Excellence (NICE) guideline that actually bases their recommenda-
tions on in-depth cost-beneficial analyses (National Institute for Health
and Care Excellence (NICE), 2013). Finally, it is worthwhile under-
lining that this point is also included in the ‘Choosing Wisely’ initia-
tive list for reproductive medicine (http://www.choosingwisely.org/
societies/american-society-for-reproductive-medicine/). Conversely,
surgery for suspected superficial peritoneal endometriosis can be con-
sidered when infertile women complain of moderate–severe pain and
prefer to seek a conception without use of ART (Duffy et al., 2014).
The decision to offer surgery in women with infertility and pain is not
the same as those without pain.
Do not recommend controlled ovarian
stimulation and IUI in infertile women with
endometriosis at any stage (quality of the
evidence,moderate; weak suggestion)
Controlled ovarian stimulation (COS) and IUI to treat infertility associ-
ated with endometriosis at any stage should be discouraged for several
reasons.
Firstly, IUI as a treatment for infertility is been questioned regardless
of the indication. According to the latest NICE guideline (2017),
the procedure is not cost-beneficial for the treatment of infertility.
It can be considered only for conditions that cannot be defined as
proper infertility, such as HIV discordance, semen donation, and sexual
disturbances (Royal College of Obstetricians and Gynaecologists,
2013). Secondly, the use of IUI for endometriosis-related infertility
is not supported by scientific evidence. The procedure was initially
advocated based on low quality studies (Deaton et al., 1990; Fedele
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et al., 1992; Nulsen et al., 1993; Omland et al., 1998; Tummon et al.,
1997; Werbrouck et al., 2006). To note, in some of these studies,
there was no attempt to differentiate women with unexplained
infertility and those with endometriosis stages I and II, while, in
others, endometriosis was considered together with other causes
of infertility, such as mild male factor or ovulatory dysfunctions.
Interestingly, a recent comparative non-randomized study failed to
show any difference betweenCOS and IUI, and expectantmanagement
(Gandhi et al., 2014). Moreover, the results of a systematic review
and meta-analysis conducted by Hughes (1997) suggest that IUI
effectiveness is halved in women with early endometriosis. Overall,
first-cycle chance of pregnancy with IVF is significantly higher than
the cumulative pregnancy rate that can be obtained after six IUI
cycles (Dmowski et al., 2002). This is somehow not surprising as
the procedure lacks a biological rationale; IVF, but not IUI, can be
expected to overcome the detrimental effects of a pelvic inflammatory
milieu.
Lastly, the risk of endometriosis recurrence appears to be increased
by IUI (Van der Houwen et al., 2014) and was reported to be higher
than after IVF D’Hooghe et al., (2006). Robust explanations for this
surprising finding are, however, lacking and further evidence is needed
(Somigliana et al., 2017).
The use of COS–IUI for endometriosis-associated infertility should
not be recommended because, according to the available evidence,
the procedure is debatable per se, the effect size appears negligible
and the procedure may expose women to an increased risk of disease
recurrence.
Do not remove small ovarian
endometriomas (diameter<4 cm) with the
sole objective of improving the likelihood of
conception in infertile patients scheduled for
IVF (quality of the evidence, high; strong
suggestion)
Ovarian endometriosis has been suggested to perturb ovarian respon-
siveness to hyper-stimulation and to interfere with folliculogenesis
(Sanchez et al., 2014). Maneschi et al. (1993) firstly hypothesize that
endometriomas could impair ovarian function. This seems unquestion-
able for large cysts (Coccia et al., 2014; Ferrero et al., 2017), but may
occur also in the case of small (<4 cm) endometriomas (Benaglia et al.,
2009). Interestingly, serum anti-Müllerian hormone (AMH) was shown
to be slightly lower in womenwith ovarian endometriomas, particularly
in case of bilateral lesions (Somigliana et al., 2014; Goodman et al.,
2016).
On the other hand, after surgery for ovarian endometriotic cysts
serum AMH levels are decreased (Raffi et al., 2012; Somigliana et al.,
2012), spontaneous ovulation is reduced (Loh et al., 1999; Candiani
et al., 2005; Horikawa et al., 2008), and the response to ovarian hyper-
stimulation is lowered (Gupta et al., 2006; Somigliana et al., 2011),
particularly in case of recurrent ovarian endometriomas (Ferrero et al.,
2015). Ovarian responsiveness is crucial for the success of IVF (Polyzos
and Sunkara, 2015) and, according to Sugita et al. (2013), the decrease
in ovarian reserve may not be limited to the immediate post-operative
period because of removal of ovarian cortex but may be progressive
with time based on different pathogenic mechanisms.
4 Zupi
When women with endometriomas were randomized to surgery
or expectant management before IVF, a reduced ovarian responsive-
ness was observed in the former group (Demirol et al., 2006). No
significant difference emerged in pregnancy rates, but the study was
underpowered for this outcome. Larger RCTs are lacking but may be
now considered ethically questionable. In fact, according to the results
of systematic literature reviews, surgical excision of small endometri-
omas before IVF is associated with a need for higher amounts of
gonadotrophins, lower peripheral estrogens levels, reduced number
of follicles, and lower number of oocytes retrieved, but no effect
on the chances of pregnancy (Brink Laursen et al., 2017; Tao et al.,
2017; Nickkho-Amiry et al., 2018). Excision of small endometriomas
before IVF is particularly discouraged in case of repetitive surgery or
bilateral cysts. However, surgery remains mandatory in the presence of
non-reassuring sonographic findings and can be considered in women
with moderate to severe pelvic pain. How to manage women carrying
asymptomatic endometriomas >4 cm should be clarified. In fact, for
large endometriomas there is a high risk of cyst puncture and rupture
during the oocyte retrieval. Evidence on new, more conservative,
surgical techniques (that avoid the removal of the cyst wall such as laser
vaporization) is still insufficient to draw suggestions (Candiani et al.,
2018).
Do not remove uncomplicated deep
endometriotic lesions in asymptomatic
women, and also in symptomatic women not
seeking conception when medical treatment
is effective and well tolerated (quality of the
evidence,moderate; weak suggestion)
‘Endometriosis should not be treated just because it’s there’ (Thomas,
1993). This is even truer when extirpative surgery is associated with
major intra- and post-operative complications and when progression
is unlikely. Complications occur in 3–10% of patients undergoing deep
endometriosis removal and include (but are not limited to) incidental
bowel, bladder, and ureteral injury, neurogenic bowel and bladder dys-
function and, in case of colorectal resection, anastomotic dehiscence,
and rectovaginal fistula formation (Vercellini et al., 2009a; Lebovic,
2016). Noteworthy is the fact that deep invasive endometriosis does
not progress in more than 9 out of 10 affected women (Fedele et al.,
2004). Therefore, removal of uncomplicated (i.e. not causing ureteral
or bowel stenosis) deep lesions in women without symptoms, or when
symptoms can be effectively handled with medical therapy, appears
unjustified, especially when conception is not an issue.
The management of deep endometriosis should be individualized
considering clinical presentation, symptom severity, disease extent and
location, reproductive desire, patient age, medication side effects,
surgical complication rates, risk of recurrence, costs, and patient pref-
erence (Lebovic, 2016). We believe that deep endometriosis is rarely
asymptomatic but can be treated effectively and safely with hor-
monal drugs in at least two-thirds of cases (Vercellini et al., 2016,
2017). Maximization of medical treatment use is supported also by
the American Society for Reproductive Medicine (Practice Committee
of the American Society for Reproductive Medicine, 2014). Surgery is
mandatory in case of hydroureteronephrosis and sub-occlusive bowel
stenosis (complicated deep endometriosis) and in highly symptomatic
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women wishing a natural conception and declining IVF (Dunselman
et al., 2014).
Most guidelines recognize the benefits of surgery on deep lesions
related pain, but also recommend to treat this subset of patients in
tertiary care and referral centers of expertise adopting a multidisci-
plinary approach including urologists and colorectal surgeons (Leyland
et al., 2010; Brown and Farquhar, 2014; Dunselmann et al., 2014).
In particular, intestinal and pain complaints improved substantially
in most women (71–93%) who underwent colorectal resection for
bowel endometriosis (Seracchioli et al., 2007; Wills et al., 2008; De
Cicco et al., 2011). However, inappropriate or non-radical surgery may
incompletely relieve or even worsen bowel symptoms (Berlanda et al.,
2016). Medications used for deep endometriosis are symptomatic, do
not cure the disease, and may be associated with untoward effects and
adverse events.
The final decision on whether to undertake long-term medical ther-
apy or complex surgery must be shared with the patient after a
complete, detailed, and unbiased sharing of information.
Do not systematically request second-level
diagnostic investigations in women with
known or suspected non-subocclusive
colorectal endometriosis or with symptoms
responding to medical treatment (quality of
the evidence, low;weak suggestion)
Transvaginal sonography (TVS) has been demonstrated to be accurate
and reliable in the identification and follow-up of deep endometriosis
infiltrating the bowel. According to a systematic review and meta-
analysis, the sensitivity and specificity of TVS in detecting rectosigmoid
endometriosis were 91% and 98%, respectively (Hudelist et al., 2011).
Several authors observed a diagnostic accuracy of TVS similar to that of
MRI in the detection of deep bowel endometriosis (Bazot et al., 2007;
Exacoustos et al., 2017; Maiorana et al., 2011; Medeiros et al., 2015).
Accordingly, MRI should be suggested as a complementary investiga-
tion only in selected women with doubtful TVS findings (Exacoustos
et al. 2014).
Enhanced ultrasonographic techniques, such as rectal water contrast
and/or sonovaginography, have also been proposed to improve the
accuracy of TVS. However, in a systematic review and meta-analysis,
the pooled sensitivity, specificity, positive and negative likelihood ratios
of TVS in detecting deep endometriosis infiltrating the rectosigmoid
were 91% (95% CI, 85–94%), 97% (95% CI, 95–98%), 33% (95%
CI, 19–59%), and 0.10% (95% CI, 0.06–0.16%), respectively, without
statistically significant differences between TVS and enhanced TVS
(Guerriero et al., 2016). Finally, Savelli et al. (2011) compared double-
contrast barium enema (DCBE) and TVS for the detection of bowel
lesions, and reported a sensitivity of, respectively, 43% versus 91%, a
negative predictive value of 6% versus 29%, and an overall accuracy of
45% versus 91%. Furthermore, TVS showed a better agreement with
histology then DCBE (Cohen’s K, 0.413 versus 0.04).
Considering the demonstrated high overall accuracy, TVS should
be considered the first-line imaging technique for the detection and
follow-up of non-sub-occlusive bowel endometriosis. (College of
Obstetricians and Gynecologists (ACOG) 2010; Leyland et al., 2010;
Dunselman et al., 2014; Guerriero et al., 2016). Conversely, in women
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with sub-occlusive symptoms, second-line assessments, such as DCBE,
multi-detector computerized tomography enema or MRI with rectal
contrast, can be proposed to investigate the presence and degree of
stenosis of the rectosigmoid junction and sigma. Colonoscopy and
rectosigmoidoscopy should be recommended in selected cases for the
evaluation of mucosal involvement and for the exclusion of primary
intestinal malignancies.
The presence of non-subocclusive endometriotic bowel infiltration
does not justify per se major intestinal procedures. Therefore, addi-
tional invasive and expensive diagnostic tests do not seem justified.
The clinician should be guided by a patient’s symptoms and, unless
a malignant lesion is suspected or a surgical procedure planned, the
results of second-level diagnostic investigations would not change
the management anyway but would add discomfort and anxiety. This
suggestion may only be questioned in context of insufficient expertise
with TVS.
Do not recommend repeated follow-up
serum CA-125 (or other currently available
biomarkers) measurements in women
successfully using medical treatments for
uncomplicated endometriosis in the absence
of suspicious ovarian cysts (quality of the
evidence, low;weak suggestion)
According to the ESHRE guideline, clinicians are recommended not
to use peripheral biomarkers, including CA-125, in plasma, urine or
serum and/or biomarkers in endometrial tissue, menstrual or uterine
fluids to diagnose endometriosis (Dunselman et al., 2014). None of the
available biomarkers consistently met the criteria for a replacement or
triage diagnostic test (Nisenblat et al., 2016) either for detecting pelvic
endometriosis or for differentiating ovarian endometrioma from other
benign ovarian masses.
The use of CA-125 measurements to monitor the course of
endometriosis during medical treatments is sometimes used in
clinical practice, but this practice is not supported by robust data.
Fedele et al. (1988) evaluated the accuracy of serum CA-125
measurements in detecting endometriosis recurrence diagnosed at
follow-up laparoscopy and failed to highlight significant benefits. The
reliability of a positive (> 35 U/mL) or negative CA-125 test was
compared with that of presence/absence of pain symptoms, and
of abnormal/normal findings at gynecologic examination. Sensitivity
and specificity of serum CA-125 measurements in the diagnosis of
endometriosis recurrence were 15% and 100%, respectively. On the
other hand, sensitivity and specificity of pain relapse were 71% and
80%, respectively, and those of abnormal physical examination were
82% and 41% (Fedele et al., 1988).
The value of serum CA-125 variations as a modality to monitor
the response to medical therapy are controversial, with some studies
suggesting a good predictive value for disease progression (Nagamani
et al., 1992; Garzetti et al., 1994; Ozaksit et al., 1995) and recurrence
(Chen et al., 1998), and others failing to observe useful correlations
(Marana et al., 1990; Lanzone et al., 1991; Ozaksit et al., 1995). No
data are available on CA-125 monitoring during use of estrogen–
progestin pills or progestins.
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Therefore, the follow-up of women with uncomplicated disease
forms (without bowel stenosis or obstructive uropathy) and with-
out suspicious adnexal masses should be based on history, physical
examination, and ultrasonography. The addition of ‘routine’ serial
biomarkers’ serum level determinations does not consistently improve
endometriosis management, but inevitably increases costs and the
overall burden of treatment. Such an approach might theoretically
benefit a small minority of patients, but in practice most women
would not be helped, and some would be harmed. In fact, the detec-
tion of serum CA-125 levels >35 U/mL may generate anxiety and
would inevitably trigger a cascade of further testing and investiga-
tions and might even result in the performance of needless laparo-
scopies.
Do not leave women undergoing surgery for
ovarian endometriomas and not seeking
immediate conception without
post-operative long-term treatment with
estrogen–progestins or progestins (quality of
the evidence, high; strong suggestion)
A cyst recurrence rate of ∼10% per year has been reported after
surgery for ovarian endometriomas (Chapron et al., 2002; Koga et al.,
2006; Liu et al., 2007; Guo, 2009; Koga et al., 2015). Women who
underwent repeat surgery were more likely to need assisted con-
ception and reported more irregular menstrual cycles associated with
FSH concentrations ≥14 UI/ml (Fedele et al., 2006; Gelbaya and
Nardo, 2011). Second-line surgery determines cumulative damage to
the ovarian reserve and is followed by a reduced likelihood of natural
conception (Vercellini et al., 2009c). Therefore, every effort should be
put in place to prevent repeat ovarian procedures.
As endometriomas appear to develop from ovarian follicles and
corpora lutea (Vercellini et al., 2009b), inhibition of ovulation with
oral contraceptives (OCs) or progestins should decrease the risk of
cyst recurrence (Seracchioli et al., 2009). Indeed, based on a meta-
analysis of comparative studies, the pooled OR of post-operative
endometrioma recurrence was 0.12 (95% CI: 0.05–0.29) in long-
term OC users compared with never OC users (Vercellini et al.,
2013). In RCTs and systematic reviews, no significant differences
were detected between cyclic and continuous OC use in terms
of cyst recurrence rate (Muzii et al., 2011, 2016; Seracchioli et al.,
2009, 2010). As expected, better results were observed with
continuous use when the considered outcome was dysmenorrhea
(Muzii et al., 2016).
The protective effect of OCs rapidly vanishes after drug with-
drawal (Vercellini et al., 2008). Once ovulations re-initiate, women are
exposed each month to a low but consistent risk of endometrioma
recurrence. Such a risk is justified in women seeking a natural preg-
nancy, otherwise tertiary prevention is recommended particularly in
patients wishing a conception in the future, unless OCs and progestins
are contraindicated or not tolerated. The use of OCs for long periods
of time after surgery to reduce lesion and pain recurrences is sug-
gested also by international guidelines (Leyland et al., 2010; Dunselman
et al., 2014; National Institute for Health and Care Excellence (NICE),
2017).
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Do not perform laparoscopy in adolescent
women (<20 years) with moderate–severe
dysmenorrhea and clinically suspected early
endometriosis without prior attempting to
relieve symptoms with estrogen–progestins
or progestins (quality of the evidence, low;
weak suggestion)
Endometriosis is the most common cause of secondary dysmenorrhea
in adolescent women (Harel, 2012), and the prevalence of visually
confirmed endometriosis in this patient population is over 60% (Janssen
et al., 2013). Most adolescent women with endometriosis have early-
stage disease, and the most common lesions are small clear or red vesi-
cles and thin pelvic adhesions between the ovaries and the peritoneum
(Vercellini et al., 1989; Laufer et al., 2003; Leyland et al., 2010; Brosens
et al., 2013). These limited forms cannot be detected at TVS or MRI
and can be definitively diagnosed only at laparoscopy.
However, in adolescent women with moderate–severe dysmenor-
rhea, early endometriosis must always be suspected, independently
of direct visualization. Therefore, a non-surgical diagnosis must be
pursued and medical treatment started, even when TVS is negative
and physical findings are inconclusive. Provided pain symptoms are
effectively relieved, a delay in visual diagnosis is not a great concern,
given that peritoneal lesions have not been shown to progress in
the vast majority of women, and that the hormonal treatments used
to alleviate symptoms generally coincide with those used to prevent
disease progression or post-operative lesion recurrence (Evers, 2013;
Vercellini et al., 2015, 2018b). In addition, no convincing evidence is
available supporting the notion that early surgical treatment of limited
peritoneal implants modifies the natural history of endometriosis, as
well as the outcomes that matter to women, that is, pain, pregnancy,
and risk of future surgery (Templeman, 2012; Janssen et al., 2013;
Saridogan, 2017).
When endometriosis is suspected in adolescent women, non-
steroidal anti-inflammatory drugs and very low-dose OCs should
be started without delay (American College of Obstetricians and
Gynecologists (ACOG), 2005; Laufer, 2008; Saridogan, 2017; Zannoni
et al., 2016), similar to what is generally suggested in adult women
(American College of Obstetricians and Gynecologists (ACOG), 2010;
Leyland et al., 2010; Dunselman et al., 2014; Practice Committee of the
American Society for Reproductive Medicine, 2014; National Institute
for Health and Care Excellence (NICE), 2017). A response to OCs
further supports the hypothesis of early endometriosis. In such a case,
the use of low-dose OCs may be continued indefinitely also with
the aim of limiting disease progression (Zannoni et al., 2016). When
OCs used cyclically do not relieve dysmenorrhea, they may be used
continuously (Harel, 2012; Laufer, 2008; Altshuler and Hillard, 2014).
In this case, patients should be informed that OCs must be stopped
for 4–7 days if erratic bleeding occurs (tailored cycling). Laparoscopy
should be offered to adolescent women not responding to medical
therapy (Janssen et al., 2013; Dunselman et al., 2014), or when follow-
up pelvic examination and TVS or transrectal sonography suggest
endometriosis progression. If laparoscopy is eventually chosen, these
young patients must be informed that surgery cannot be expected
to provide a definitive cure (Laufer et al., 2003; American College of
Obstetricians and Gynecologists (ACOG) 2005; Zannoni et al., 2016).
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Do not prescribe drugs that cannot be used
for prolonged periods of time because of
safety or cost issues as first-line medical
treatment, unless estrogen–progestins or
progestins have been proven ineffective, not
tolerated, or contraindicated (quality of the
evidence, high; strong suggestion)
Currently used medical treatments for endometriosis include estro-
gen–progestins, progestins, and GnRH agonists (Dunselman et al.,
2014). Despite the demonstrated efficacy of these drugs in controlling
endometriosis-related symptoms, none of them is curative and symp-
toms usually recur after therapy withdrawal. Most women affected
by endometriosis should take medications even for years, discontin-
uing them only in case they wish to conceive. Consequently, physi-
cians should tailor medical treatment for endometriosis considering
patients’ preferences and aiming at long-term adherence, thus choosing
agents combining good efficacy and good tolerability (Vercellini et al.,
2016).
Among the available options, hormonal contraceptives and pro-
gestins demonstrated the most favorable safety/efficacy/tolerability/-
cost profile (American College of Obstetricians and Gynecologists
(ACOG), 2010; Leyland et al., 2010; Dunselman et al., 2014; Prac-
tice Committee of the American Society for Reproductive Medicine,
2014; National Institute for Health and Care Excellence (NICE), 2017)
and are, therefore, suitable for long-term use. Progestins can be
used in women with metabolic or cardiovascular contraindications to
estrogen–progestins and limit the risk of post-operative dysmenor-
rhea recurrence also when released locally via an intrauterine sys-
tem (Strowitzki et al., 2010; Brown et al., 2012; Petraglia et al., 2012;
Abou-Setta et al., 2013).
Themetabolic impact and the incidence and type of untoward effects
of different progestins should be considered in relation to specific
patient characteristics. As an example, progestins with androgenic
properties are not suitable for women with acne and seborrhea. The
cost of different medications should also be taken into account, as
this is a determinant of long-term treatment adherence (Vercellini
et al., 2018a, 2018b). Despite their excellent efficacy on pelvic pain
symptoms (Brown et al., 2010), GnRH agonists may not be considered
as the first-line treatment option. The profound hypo-estrogenism
induced by GnRH agonists prevents their use for prolonged periods,
particularly in younger women who may not have reached their peak
bone density (Bedaiwy et al., 2017). The association of GnRH ago-
nists with hormonal add-back therapy prevents bone loss without
decreasing their efficacy (Surrey et al., 2010). However, this approach
is associated with even higher costs and an additional therapeutic
burden.
According to systematic literature reviews and meta-analyses, as
well as recommendations of major international scientific societies, no
major differences exist between available medications for endometrio-
sis in terms of efficacy on pain (American College of Obstetricians
and Gynecologists (ACOG), 2010; Leyland et al., 2010; Dunselman
et al., 2014; Practice Committee of the American Society for Repro-
ductive Medicine, 2014; National Institute for Health and Care Excel-
lence (NICE), 2017). However, the issue deserves further studies
(Brown et al., 2010). At present, the safest, better tolerated, and
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least expensive pharmacologic solution should be initially chosen to
treat endometriosis-related symptoms, stepping up to costlier or less
safe medications only in women unresponsive, intolerant, or with
contraindications to combined hormonal contraceptives or progestins.
This stepped-care approach should be maintained even when GnRH
antagonists will soon become available.
Do not use robotic-assisted laparoscopic
surgery for endometriosis outside research
settings (quality of the evidence,moderate;
weak suggestion)
Robotic-assisted surgery (RAS) is one of the latest innovations in the
field of minimally invasive surgery. It already has many applications in
cardiac, abdominal, and urological surgery, and it has been evaluated
also for possible use in gynecological surgery.
Several RCTs have been designed in order to compare robotic-
assisted surgery and conventional laparoscopic techniques (or, when
feasible, a vaginal approach) in terms of effectiveness and safety in
patients with benign or malignant gynecological conditions. According
to a Cochrane review (Liu et al., 2014), robotic surgery, despite some
advantages (i.e. it enables three-dimensional visualization of the surgical
field, reduces or eliminates wrist motions, allows the surgeon to be
seated, and shortens the learning curve), was not shown to provide
better clinical outcomes compared with conventional laparoscopic
surgery. In particular, the risk of conversion to laparotomy and of
intraoperative complications was not reduced. RAS seems to be asso-
ciated with a moderately shorter hospitalization time, but on the other
hand, it has longer operating times and it is much more expensive.
The additional cost includes not only the cost of the instrument itself,
but also maintenance and the need for a specially trained staff. The
results of the first RCT comparing RAS and conventional laparoscopy
for endometriosis excision (Soto et al., 2017) confirm the findings of
previous observational studies (Berlanda et al., 2017). In fact, no signif-
icant differences were observed between the two surgical approaches
in terms of operative time, complications, and clinical outcomes at 1-
year follow-up.
The American College of Obstetricians and Gynaecologists
discourages the routine use of RAS for gynecological benign disor-
ders (https://www.acog.org/About-ACOG/ACOG-Departments/
Patient-Safety-and-Quality-Improvement/Choosing-Wisely). In par-
ticular, no evidence is available supporting the routine use of RAS
in patients with endometriosis, and such an approach outside
research settings should be avoided. This recommendation is currently
robust.
It should not be ruled out that, in case of future cost reduction and
an increase in the number of trained personnel, RAS might be imple-
mented in standard practice for particularly challenging and long-lasting
procedures. In particular, this may become valid in some particular
settings such as those with less laparoscopic expertise. To note, Lim
et al. (2016) recently reported the rate of conversion was lower with
robotic surgery when referring to a general community-based sample
of gynecologic surgeons. However, even if the systematic adoption of
RAS would possibly benefit surgeons, the magnitude of the effect on
patient outcomes would likely remain limited, and the costs unjustified
(Vercellini et al., 2018a, 2018b).
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Discussion
Medical overuse constitutes one of the main problems of mod-
ern medicine (Morgan et al., 2016) and several initiatives have
been launched by major medical journals and professional medical
associations to counteract this growing and widespread phe-
nomenon (http://www.choosingwisely.org; https://jamanetwork.
com/collections/44045/less-is-more; https://www.bmj.com/too-
much-medicine). Broadly defined, medical overuse may be considered
as a combination of overtesting/overdiagnosis with overtreatment that
results in an unfavorable balance between incremental benefits, risk of
harms, and cost of healthcare interventions (Moynihan et al., 2012;
Colla, 2014). Several downsides are associated with unnecessary, or
excessive, or disproportionately expensive medical measures, from
both an individual and collective perspective.
Individual people may incur needless harms without net benefits,
bear the psychological impact of disease labeling, or carry an avoidable
supplementary burden of treatment in addition to the burden
of illness (Grady and Redberg 2010; Moynihan et al., 2012; Tran
et al., 2015). From a societal point of view, the implementation
of diagnostic and therapeutic measures that do not translate into
consistent and substantial improvements in health outcomes, is
implicitly inequitable toward other patients (Oliver, 2017). Moreover,
considering that generally the healthcare resources are finite,
adopting unjustifiably expensive technologies displaces resources
in other similar patients, with a net decrease in population health
(Paulden, 2017).
Several drivers of overmedicalization have been recognized (Grady
and Redberg, 2010; Greenberg and Green, 2014). Both patients
and physicians may believe that detecting early disease and treating
even smaller abnormalities improve outcomes. Although this has not
been definitively demonstrated in women with endometriosis, such
an approach fits into the more general cultural belief that in medicine
more is better. Moreover, it may be simpler to order a test or indicate a
surgical procedure rather than take the time to explain why it would be
better to avoid thosemeasures. This attitude is facilitated by the glamor
of advanced new technology, or when gynecologists have insufficient
knowledge or confidence in managing women with endometriosis.
This last aspect is frequently linked with defensive medicine, especially
considering that underdiagnosis, but not overdiagnosis, is generally
legally prosecuted. Finally, medical overuse may be prompted by
commercial and professional vested interests, or whenever payment
systems incentives reward more tests and treatments. In this regard,
the use of diagnostic and therapeutic measures that have been proven
beneficial in a high-risk population may be expanded to lower-risk
groups in which the potential benefit does not outweigh the risk of
harm (Grady and Redberg, 2010). In fact, interventions show safety
and effectiveness features that depend on the characteristics of the
population to whom it is offered. Extrapolation of the evidence derived
from application of medical measures to specific clinical sub-groups is
inappropriate and may be encouraged by financial incentives (Elshaug
et al., 2013).
The initiative of the ETIC group is specifically aimed at limiting
medical overuse in women with known or suspected endometriosis.
The 10 measures to be avoided have been selected through the
development of a pre-planned methodological approach. Interest-
ingly, all the statements made achieved complete agreement among
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participants, without the expression of cautionary detail to be con-
sidered when evaluating or interpreting both the definition of the
statement or its strength. The present position paper is the expres-
sion of a nation-wide network of experts providing high-quality care
in all fields of endometriosis management. Therefore, the resulting
document is unlikely to be skewed toward a particular management
approach. Moreover, each suggestion is based on a critical appraisal
of the best available data and the quality of the evidence was graded
according to an internationally adopted system. On the other hand,
it has to be recognized that a possible limitation of this paper could
be the potential influences coming from our country in terms of
local costs and availability of different procedures (all participants
were Italian). Moreover, the selection of the 10 points was based
on expert opinion rather than a robust scientific approach and we
cannot exclude that other excluded points could be similarly (or more)
important.
The quality of the evidence supporting the considered points was
estimated high for four topics, moderate for three, and low for three.
The suggestion was considered strong-against for four issues and
weak-against for the remaining six. Strong suggestions were made
only when high-quality-against evidence (RCTs or systematic reviews
with meta-analyses) was available. Although 3 of the 10 suggestions
(the fifth, sixth, and eighth) are based on low-quality evidence, all
the experts agreed that overtesting and overdiagnosis is extremely
frequent in the respective circumstances, thus a statement was deemed
justified despite paucity of data derived from adequately designed
studies. Performance of any diagnostic measure should be based on the
principle that management changes in relation to the different possible
test results. In the best scenario, treatment for the above conditions
would unlikely change, thus the reason for ordering uncomfortable
and/or costly investigations is unclear. In the worst scenario, needless
and potentially harmful procedures would be indicated that might not
improve clinical outcomes.
Different diagnostic and therapeutic strategies associated with
highly variable management costs can be adopted in women with
endometriosis. To maximize the benefit from a given sum of money,
or minimize the resources required for a pre-defined benefit, low-
value diagnostic and treatment interventions, and those whose
effectiveness is comparable with less expensive alternatives, should
be recognized based on the available evidence, and de-implemented
(Vercellini et al., 2015, 2018a, 2018b). This appears particularly
important when considering that the disease may cause symptoms
for decades. The present list is certainly not exhaustive and other
relevant interventions may have been disregarded. However, we
focused on the topics that all the participants judged to be most
pertinent. We plan to update, modify, or integrate this position
paper as soon as further robust evidence on the considered
points accumulates.
Many people equate decreasing the volume of care to rationing.
However, rationing implies that the care being withheld is beneficial
and is being withdrawn exclusively to save money (Grady and Redberg,
2010). The issue here is completely different and is related to, first, the
avoidance of those procedure that have not been demonstrated to
be associated with improved outcomes and, second, use of the money
saved by de-adopting measures associated with harms or psychological
distress to improve the health of the largest possible number of
patients. Indeed, several stakeholders may profit from overdiagnosis
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and overtreatment of endometriosis. Industry influence, hospital rev-
enues, competing interests, self-referrals, and fee-for-service payment
systems, in addition to healthcare providers’ insufficient knowledge of
economic evaluation, may impact on the financial burden of disease
management shouldered by families and health services. According to
LeFevre (2013), ‘every dollar spent on health care is someone’s income
stream. In any move to do less, there will be efforts from those who
lose income to push back. [. . .] We should be able to buy more health
for the money we spend’.
Affordability also is a determinant of patients’ adherence, and
some women with endometriosis might forego care when faced
with highly expensive treatments (Vercellini et al., 2018a, 2018b).
Therapeutic individualism, especially when unsupported by good-
quality evidence, carries an implicit risk of overmedicalization and
is hardly acceptable, particularly in the context of fixed-budget
public health systems designed to provide collective coverage to the
many (Oliver, 2017). Resources wasted on unnecessary measures
can be much better spent treating those patients with severe
or refractory endometriosis forms that need continuous medical
assistance.
In addition to prevention of unnecessary medical procedures and
limitation of outcome-unrelated costs of disease management, the
reduction of the burden of treatment for women with endometriosis is
a further objective of the present list of 10 diagnostic and therapeutic
interventions to be de-implemented. The burden of treatment has
been defined as the challenges associated with everything patients
have to do to take care of themselves (Tran et al., 2015). In the
case of endometriosis, women have to deal with drug management,
self-monitoring, diagnostic measures such as laboratory tests, imaging
investigations, and endoscopic examinations, visits to the gynecol-
ogist, repeated surgical procedures, lifestyle changes, and adminis-
trative tasks to access and co-ordinate care. Hidden costs should
also be considered, as the expenses of getting to clinic appoint-
ments, taking time off work, and paying for all or some of the treat-
ments may constitute a problem (Mair and May, 2014). The quality
of life for women with endometriosis, already worsened owing to
the burden of disease, may be further deteriorated by an excessive
burden of treatment. Modifying management with the objective of
reducing the burden of treatment has the potential to improve out-
comes (Spencer-Bonilla et al., 2017). Adopting the ETIC suggestion list
might contribute to promoting a minimally-disruptive management of
endometriosis.
The evidence in support of several aspects of endometriosis
management is suboptimal. In addition to explanatory trials of
efficacy, designed mainly for registration purposes with highly selected
participants, pragmatic trials of effectiveness conducted on the
general population of endometriosis patients in routine practice
settings are badly needed to inform women’s choices (Haynes, 1999).
Moreover, cost-effectiveness studies might facilitate divestment from
interventions associated with excessive opportunity costs, where
the expected health gains do not exceed the value of the expected
health losses (Paulden, 2017). Along this line, more attention should
be given to initiatives designed to increase cost-consciousness in
endometriosis management, as this could favor a more equitable
distribution of healthcare resources among patients with different
clinical conditions. Providing high-value care, avoiding medical overuse,
and reducing the burden of treatment should be the main goals of
Ten low-value interventions for endometriosis 9
physicians caring for women with endometriosis. In the absence
of sufficiently robust data supporting the performance of specific
diagnostic and treatment interventions, the priority remains ‘first, do
no harm’.
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